K. A. Malyshkin

K. A. Malyshkin

Auto-generated profile, based on publicly available information

K. A. Malyshkin

Pavlov University

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 September 2023 in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
Verified
Journal Article
Open access
PDF file
EKE. P. Kolesova
E. P. Kolesova
MBM. A. Boyarinova
M. A. Boyarinova
AMA. L. Maslyanskiy
A. L. Maslyanskiy
KMK. A. Malyshkin
K. A. Malyshkin
SKS. V. Kibkalo
S. V. Kibkalo
AKA. O. Konradi
A. O. Konradi
In recent years, an increasing number of studies have shown a close relationship between the composition and function of the microbiota and human health, including cardiovascular diseases (CVD). Increased intestinal permeability is one of the factors that can influence the state of the microbiota and also lead to the penetration of bacteria and their toxins into the bloodstream, causing systemic inflammation. Chronic inflammation, in turn, is accompanied by increased levels of cytokines, which can cause endothelial damage and lead to endothelial dysfunction. Metabolites of some bacteria can reduce the production of molecules that regulate vascular tone, such as nitric oxide, which can lead to vasoconstriction and hypertension. The review focuses on the connection between calprotectin, zonulin, and trimethylamine oxide with the risk of CVD, and also highlights possible methods for correcting the composition and function of the microbiota for the prevention of CVD.

21 December 2021 in Russian Clinical Laboratory Diagnostics
Verified
Journal Article
Open access
VSV. I. Smirnova
V. I. Smirnova
SLSergey V. Lapin
Sergey V. Lapin
DLD. G. Lebedev
D. G. Lebedev
VEV. L. Emanuel
V. L. Emanuel
KMK. A. Malyshkin
K. A. Malyshkin
TBT. V. Blinova
T. V. Blinova
The aim of this study was to validate the method for analyzing the composition of calculus using infrared (IR) spectroscopy by studying model mixtures of salts. Study was made with an ALPHA-P IR Fourier spectrometer with OPUS software (Bruker, Germany). The samples of pure chemical salts manufactured by Sigma-Aldrich USA were used to validate the method. Salt mixtures were prepared in ratios of 10/90, 50/50 and 90/10. To assess the effect of the fraction size on the calculus component results, were used calculi of patients with urolithiasis. For each mixture were used 10 repeated measurements. Analysis of the composition of model salts showed that in the study of pure cystine salt CV(%) was 0,79%, calcium carbonate - 0,92%, sodium urate - 0,97%, calcium oxalate monohydrate - 4,94%, magnesium ammonium phosphate - 5,59%. And the most common components were analyzed in the composition of complex mixtures, including 90%, 50% and 10% of the investigated component. Calcium oxalate monohydrate has CV(%) 5.70% in mixture 9 part of it to one part of impurities, in mixture 50/50 - 21.57% and in 10/90 - 5.70%. For uric acid in 90/10 - 2.20%, in 50/50 - 10.09%, in 10/90 - 31.94%. For calcium carbonate in 90/10 - 9.02%, in 50/50 - 11.98%, in 10/90 - 24.70%. The dispersion analysis showed that the weighed portions of salts with a particle diameter of more than 0.8 mm provide reproducibility with a CV - 11.48%, with a diameter of 0.2-0.8 mm - 5.35%, and finally less than 0.1 mm - 2.28%. The accuracy of the method is high, but the reproducibility of the IR-spectroscopy method is relatively low in the analysis of stones of mixed composition, due to the greater error in the determination of impurities. Laboratories should pay special attention to optimizing sample preparation to ensure particle fineness less than 0.1 mm.

9 April 2026 in "Arterial’naya Gipertenziya" ("Arterial Hypertension")
Verified
Journal Article
Open access
PDF file
EKE. P. Kolesova
E. P. Kolesova
AMA. L. Maslyanskiy
A. L. Maslyanskiy
YTYana Toropova
Yana Toropova
Yury A. SkorikYury A. Skorik
Yury A. Skorik
KMK. A. Malyshkin
K. A. Malyshkin
ESE. V. Shlyakhto
E. V. Shlyakhto
Background . Colchicine, traditionally used for gout treatment, has recently emerged as a promising therapeutic option for coronary artery disease (CAD) due to its anti-inflammatory properties. However, its use is accompanied by conflicting clinical data and potential risks. Objective . To systematize current evidence on the efficacy and safety of colchicine in cardiovascular diseases, identifying key areas of certainty and uncertainty. Design and methods . We analyzed 35 clinical studies (2021-2025), including randomized controlled trials (LoDoCo2, COLCOT, CLEAR), meta-analyses and cohort studies. The study was supported by the Russian Science Foundation (Agreement No. 25-15-20110). Results . Proven benefits: 28 % reduction in cardiovascular events in chronic CAD; atherosclerotic plaque stabilization (+ 34,2 μm fibrous cap thickness); 33 % reduction in postoperative atrial fibrillation. Controversial data: no benefit in acute coronary syndrome (odds ratio (OR) 0,99); increased dementia risk with long-term use (OR 1,45). Safety concerns: gastrointestinal complications (+ 3,6 %); trend toward increased non-cardiac mortality (+ 38 %); dose-dependent increase in dementia risk (+ 45 %). Conclusion . Colchicine represents a promising tool for secondary prevention of atherothrombosis, combining centuries of clinical experience with modern understanding of inflammatory mechanisms. Its niche included patients with chronic CAD and persistent inflammatory activity, where it complements standard therapy without increasing bleeding risk, unlike more aggressive antithrombotic strategies. Further research should clarify its role in acute settings and optimize dosing regimens considering individual safety profiles.